Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen
Treatment for HIV/AIDS - Drug-susceptible Tuberculosis
Typical Dosage: Weight-based daily dosing for Rifapentine, Moxifloxacin, Isoniazid, Pyrazinamide
Effectiveness
88%
Safety Score
55%
Clinical Trials
50
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Weight-based daily dosing for Rifapentine, Moxifloxacin, Isoniazid, Pyrazinamide
Time to Effect
1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion
Treatment Duration
4 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,160
Monitoring:$1,500
Side Effect Mgmt:$400
Total Annual:$3,060
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$7,500/QALY
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$3,477
Cost per Remission
$3,687
Comparison vs Standard 6-month HRZE/HR Regimen
Cost Difference
$-270/year
Less expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen Outcomes
for HIV/AIDS - Drug-susceptible Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+83%
Common Side Effects
Gastrointestinal upset (nausea, vomiting, diarrhea)
+20%
Hepatotoxicity (elevated LFTs, hepatitis)
+8%
Peripheral neuropathy
+5%
Orange/red discoloration of urine/tears/sweat
+99%
Rash
+7%
QT prolongation
+1%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov